So, the in-house eye programme is progressing. I understand the timeframe to deliver a drug is 4 years - 6 months to select CPP, 6 months for IND approval, 3 years of human trials/approvals. It begs a few questions - at what point do we see some commercial outcome (4 years?), at what point and at what cost will we chase new capital, where are the outsource programmes (CRISPR, Herpes). I understood the strategy was to develop an in house drug (Eye) and an outsourced technology (CRISPR, Herpes and ...). There is no mention of these in the presentation. Someone give me comfort that we won’t be waiting another 4 years for a commercial return - that will take us into the realm of a 20 year investment (March 2004 float). For the first time in 15 years I have moved off BUY sentiment (to HOLD) and seriously considering SELL sentiment and action.
- Forums
- ASX - By Stock
- Ann: Animal Models - 400% Outperformance of Gold Standard
So, the in-house eye programme is progressing. I understand the...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.5¢ |
Change
0.010(8.70%) |
Mkt cap ! $583.2M |
Open | High | Low | Value | Volume |
12.0¢ | 12.5¢ | 12.0¢ | $211.9K | 1.749M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 596329 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 828969 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 596329 | 0.120 |
18 | 1064583 | 0.115 |
15 | 699437 | 0.110 |
19 | 1664927 | 0.105 |
20 | 1469683 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 828969 | 8 |
0.130 | 443426 | 5 |
0.135 | 784759 | 6 |
0.140 | 781287 | 9 |
0.145 | 443572 | 9 |
Last trade - 14.28pm 09/09/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |